Why Cencora (COR) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?
Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Cencora, Inc. (COR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Cencora, Inc. (NYSE:COR ) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 11:30 AM EDT Company Participants James Cleary - Executive VP & CFO Bennett Murphy - Senior VP, Head of Investor Relations & Treasury Conference Call Participants Erin Wilson Wright - Morgan Stanley, Research Division Presentation Erin Wilson Wright Equity Analyst Good afternoon, everyone. Welcome to Day 3 of the Morgan Stanley Healthcare Conference.
Here's Why Cencora (COR) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Is Climb Bio, Inc. (CLYM) Outperforming Other Medical Stocks This Year?
Here is how Climb Bio, Inc. (CLYM) and Cencora (COR) have performed compared to their sector so far this year.
Why Cencora (COR) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cencora: Yet Another Strong Quarter, But Valuations Still Aren't Cheap
Cencora delivered strong quarterly results and guidance upgrades, but expectations need to be moderated as these results should fade in the coming quarters. The valuation remains elevated at 17.9x forward P/E, well above the 5-year average, making the risk/reward unattractive at current levels. Key risks include heavy revenue exposure to Walgreens Boots Alliance, which faces solvency issues and plans to sell its COR stake.
3 Reasons Growth Investors Will Love Cencora (COR)
Cencora (COR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Cencora Q3: Growing Specialty Drug Distributions, Initiate At Buy
I initiate Cencora, Inc. with a Buy rating and a fair value of $337, due to its stable business model and strategic specialty drug expansion. Cencora's acquisition of Retina Consultants of America and focus on GLP-1 drugs strengthen its specialty solutions, supporting long-term growth and margin improvement. Management's commitment to digital infrastructure and specialty expertise positions Cencora to benefit from robust U.S. pharmaceutical sales growth and healthcare trends.
Cencora, Inc. (COR) Q3 2025 Earnings Call Transcript
Cencora, Inc. (NYSE:COR ) Q3 2025 Earnings Conference Call August 6, 2025 8:30 AM ET Company Participants Bennett S. Murphy - Senior VP, Head of Investor Relations & Treasury James F.
COR Q3 Earnings & Revenues Beat Estimates, '25 EPS View Raised
Cencora posts strong Q3 results with earnings and revenues surpassing estimates; raises FY25 EPS guidance on robust U.S. segment growth.
Cencora (COR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Cencora (COR) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
